Section Arrow
Quote
APLS.NASDAQ
- Apellis Pharmaceuticals
Quotes are at least 15-min delayed:2024/12/25 01:12 EST
Last
 33.32
+0.11 (+0.33%)
Day High 
33.39 
Prev. Close
33.21 
1-M High
35.72 
Volume 
437.76K 
Bid
32.31
Ask
33.32
Day Low
32.5 
Open
33.21 
1-M Low
31.0913 
Market Cap 
4.13B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 33.63 
20-SMA 33.75 
50-SMA 30.29 
52-W High 73.8 
52-W Low 24.34 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.03/-1.33
Enterprise Value
4.24B
Balance Sheet
Book Value Per Share
1.91
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
396.59M
Operating Revenue Per Share
2.19
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.3853-0.0178-4.42%-- 
CMNDClearmind Medicine1.72+0.5+40.98%0.16PE
CEROCERo Therapeutics Holdings0.0623+0.0118+23.37%-- 
ATNF180 Life Sciences Corp2.9+1.03+55.08%0.23PE
RXRXRecursion Pharmaceuticals7.24+0.25+3.58%-- 
Quotes are at least 15-min delayed：2024/12/25 01:12 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.